Compare MSCI & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSCI | ALC |
|---|---|---|
| Founded | 1998 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 39.0B |
| IPO Year | 2007 | N/A |
| Metric | MSCI | ALC |
|---|---|---|
| Price | $575.94 | $78.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $658.50 | $88.29 |
| AVG Volume (30 Days) | 531.4K | ★ 1.5M |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.44% | 0.27% |
| EPS Growth | ★ 11.67 | N/A |
| EPS | ★ 15.69 | 2.10 |
| Revenue | $3,134,459,000.00 | ★ $10,185,000,000.00 |
| Revenue This Year | $11.53 | $5.76 |
| Revenue Next Year | $8.04 | $7.24 |
| P/E Ratio | ★ $36.39 | $37.09 |
| Revenue Growth | ★ 9.74 | 4.34 |
| 52 Week Low | $486.74 | $71.55 |
| 52 Week High | $626.28 | $99.20 |
| Indicator | MSCI | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 46.02 |
| Support Level | $558.62 | $76.95 |
| Resistance Level | $626.28 | $79.67 |
| Average True Range (ATR) | 18.46 | 1.13 |
| MACD | -3.41 | -0.28 |
| Stochastic Oscillator | 21.95 | 36.99 |
MSCI has described its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. MSCI boasts about $17 trillion in benchmarked assets, including over $2.2 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. In its sustainability and climate segment, MSCI provides ESG data to the investment industry. In private assets, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.